VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals via VEGF receptor Type 2-Reference-Cited by-同舟云学术

VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals via VEGF receptor Type 2

Published:2011-05-25 Issue:4 Volume:130 Page:857-864
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Ziogas Apostolos C.,Gavalas Nikos G.,Tsiatas Marinos,Tsitsilonis Ourania,Politi Ekaterini,Terpos Evangelos,Rodolakis Alexandros,Vlahos George,Thomakos Nikolaos,Haidopoulos Dimitrios,Antsaklis Aristidis,Dimopoulos Meletios A.,Bamias Aristotle

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference21 articles.

1. Angiogenic inhibitors: A new therapeutic strategy in oncology;Gasparini;Nat Clin Pract Oncol,2005

2. Vascular endothelial growth factor induces tissue factor and matrix metalloproteinase production in endothelial cells: Conversion of prothrombin to thrombin results in progelatinase A activation and cell proliferation;Zucker;Int J Cancer,1998

3. VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis;Tam;Nat Med,2006

4. Vascular endothelial growth factor: Basic science and clinical progress;Ferrara;Endocr Rev,2004

5. Tumorigenesis and the angiogenic switch;Bergers;Nat Rev Cancer,2003

Cited by 138 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. References;The Evolution of Immunotherapy Against Tumors;2025

2. Natural products‐based antiangiogenic agents: New frontiers in cancer therapy;Food Frontiers;2024-09

3. Mechanisms of resistance to tyrosine kinase inhibitor‐targeted therapy and overcoming strategies;MedComm;2024-08-24

4. Effectiveness and safety of anlotinib plus anti-programmed cell death 1/ligand 1 (anti-PD-1/PD-L1) antibodies as maintenance therapy after first-line chemotherapy combined with anti-PD-1/PD-L1 antibodies in extensive-stage small cell lung cancer: a real-world study;Journal of Thoracic Disease;2024-07

5. Shedding light on the role of LAG-3 in hepatocellular carcinoma: unraveling immunomodulatory pathways;Hepatoma Research;2024-04-26